Clinical trials in cluster headache and migraine have supported the reported efficacy and safety of psilocybin in the transitional treatment of these disorders, according to an evidence perspective published in Nature Reviews Neurology. Authors Erik Zorrilla and Emmanuelle A. D. Schindler emphasize that psychedelic compounds are re-emerging as potential therapeutic options across headache medicine, showing particular clinical relevance for cluster headache.
Headache disorders are common neurological conditions with numerous treatment options that vary according to the specific disorder and the distinct needs of each individual. The authors observe that the renewed scientific and clinical interest in psychedelic treatments for headache is largely attributable to the patient community, whose members have consistently advocated for their preferred forms of management, including psychedelic medications.
In addition to psilocybin, compounds such as dimethyltryptamine and lysergic acid diethylamide have played important historical roles in headache medicine. The Perspective reviews this historical context, the documented chronology of major events linking psychedelics to headache care, and the proposed mechanisms of action for these agents. The authors also evaluate how psychedelics relate to conventional headache medications, observing that further studies investigating other compounds and modes of treatment are already ongoing or on the horizon.
Despite these developments, the authors stress that the clinical and scientific evidence available to date remains limited in scope. Significant safety, logistical, and legal concerns also surround the use of psychedelic compounds, requiring careful evaluation to resolve existing challenges and set the stage for rigorous future work in the field of headache medicine.
Subject of Research: Psychedelic drug therapies in headache medicine
Article Title: Psychedelic treatment for headache disorders
Article References: Zorrilla, E., & Schindler, E. A. D. (2026). Psychedelic treatment for headache disorders. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01285-w
Image Credits: AI Generated
DOI: 10.1038/s41582-026-01285-w
Keywords: headache disorders, psilocybin, cluster headache, migraine, dimethyltryptamine, lysergic acid diethylamide, psychedelic medicine, transitional treatment, clinical trials, neurology, patient advocacy, mechanisms of action, conventional headache medications, headache chronology, drug safety, treatment efficacy
News Source: Ophelia Keating. (November 17, 2026). Trials Support Psilocybin for Transitional Cluster Headache and Migraine Treatment. Scienmag.



